Amgen Inc (AMGN)
Operating return on assets (Operating ROA)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Operating income | US$ in thousands | 7,258,000 | 7,897,000 | 5,335,000 | 6,005,000 | 5,794,000 |
Total assets | US$ in thousands | 91,839,000 | 97,154,000 | 65,121,000 | 61,165,000 | 62,948,000 |
Operating ROA | 7.90% | 8.13% | 8.19% | 9.82% | 9.20% |
December 31, 2024 calculation
Operating ROA = Operating income ÷ Total assets
= $7,258,000K ÷ $91,839,000K
= 7.90%
Amgen Inc's operating return on assets (operating ROA) has shown a slight fluctuation over the past five years. The percentage ranged from 9.20% at December 31, 2020, to 7.90% at December 31, 2024. The declining trend indicates that the company may be experiencing challenges in generating operating profits from its assets efficiently. Further analysis of the company's operating efficiency, asset utilization, and profitability drivers may be necessary to understand the factors contributing to this trend.
Peer comparison
Dec 31, 2024
Company name
Symbol
Operating ROA
Amgen Inc
AMGN
7.90%
ADMA Biologics Inc
ADMA
28.44%
Bio-Techne Corp
TECH
7.64%
Biogen Inc
BIIB
-0.81%
Gilead Sciences Inc
GILD
2.82%
Halozyme Therapeutics Inc
HALO
26.73%
Krystal Biotech Inc
KRYS
6.22%
Moderna Inc
MRNA
-27.90%
Neurocrine Biosciences Inc
NBIX
15.34%
Repligen Corporation
RGEN
-1.24%
Vericel Corp Ord
VCEL
1.04%